1 / 18

A population-based surveillance study on the prevalence and treatment of hepatitis C in Estonia

A population-based surveillance study on the prevalence and treatment of hepatitis C in Estonia. Kairi Mansberg PhD student University of Tartu, Department of Internal Medicine. Background.

norris
Download Presentation

A population-based surveillance study on the prevalence and treatment of hepatitis C in Estonia

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. A population-based surveillance study on the prevalence and treatment of hepatitis C in Estonia Kairi Mansberg PhD student University of Tartu, Department of InternalMedicine

  2. Background • hepatitis C infection is a significant public health problem and a leading cause of chronic liver disease in Estonia • Estonian Society of Gastroenterology • multi-center, non-interventional study • study cohort of consecutive patients with: • acute hepatitis C • chronic hepatitis C • C-related cirrhosis or • C-related hepatocellular carcinoma • represents the real-life situation • duration 30 months,01.02.2009 - 31.07.2011

  3. Aims • To characterize the patients with hepatitis C • To analyse the real-life hepatitis C cohort of patients • To describe the risk factors of hepatitis C • To analyse the efficacy and safety of antiviral treatment in real-life situation

  4. Material and methods (1) • patients with HCV infection • consecutively referred as in-patients and out-patients • were recruited in 7 divisions of 5 hospitals • by 31 gastroenterologists / infectious disease doctors • patients were required to meet the criteria of: • acute hepatitis C • chronic hepatitis C • C-related cirrhosis or • C-related hepatocellular carcinoma

  5. Material and methods (2) • patients were included during a 1-year recruitment period, 01.02.2009-31.01.2010 • follow-up period lasts 1,5 years, till 31.07.2011

  6. Material and methods (3) • Ethics Review Committee on Human Research of the University of Tartu approval was obtained • informed consent was obtained from all patients • patients were given 24 or 48 weeks of standard therapy (combination of pegylated interferon alfa-2a or alfa-2b and ribavirin), depending on the genotype

  7. Material and methods (4) web-based electronic Case Report Form (eCRF) is used for data registration data are entered into an eCRF by doctors in the course of the study, the study monitor visits the sites to verify eCRFs against source documentation monitoring is conducted in each study center 4 times per year data analysis is based on descriptive statistics

  8. Results (1)Patients number of patients: 544

  9. Results (2)Mean age by gender

  10. Results (3) Distribution by age and gender

  11. Where the patients come from?

  12. Risk factors of infection of hepatitis C virus • For the majority of patients, the route of infection remains unknown • 158 patients potentially were infected via blood transfusion before 1994

  13. Distribution of genotypes

  14. Diagnosis

  15. Antiviral treatment

  16. Conclusions (1) • For the first time in Estonia the comprehensive dataset of the cohort of 544 HCV patients is created and can be analysed • Out of 544 included patients, 247 (45%) started antiviral treatment; respective dataset is created and can be further analysed

  17. Conclusions (2) the majority of patients do not know where and when they got the hepatitis C potential transmission of HCVvia blood transfusion before 1994 was reported most often genotype 1 is the most prevalent genotype in Estonia (69,5% of all patients), followed by genotypes 3 and 2 (24,5% and 5,9% respectively)

More Related